Skip to content

Government belongs to the people.

If it governs your life, you should have a voice in it.

Official voting resourcesVote.gov ↗USA.gov ↗
All federal
19,857 total · sort: latest action
H.R. 1013 · HOUSE2d
Retirement Fairness for Charities and Educational Institutions Act of 2025
Rule H. Res. 1650 passed House.
H.Res. 1654 · HOUSE3d
Congratulating the Milwaukee Brewers, and the fans of the Milwaukee Brewers, on winning Major League Baseball's 2026 World Championship Series.
Referred to the House Committee on Oversight and Government Reform.
H.Res. 1653 · HOUSE3d
Honoring the service and sacrifice of America's veterans on Veterans Day, 2026.
Referred to the House Committee on Veterans' Affairs.
H.R. 10964 · HOUSE3d
To designate the facility of the United States Postal Service located at 2503 South Washington Avenue in Titusville, Florida, as the "Agent Kevin Morris Post Office".
Referred to the House Committee on Oversight and Government Reform.
H.R. 10967 · HOUSE3d
Diwali Day Act
Referred to the House Committee on Oversight and Government Reform.
H.Res. 1651 · HOUSE3d
Supporting the goals and ideals of "National Veterans Small Business Week".
Referred to the House Committee on Small Business.
H.R. 10963 · HOUSE3d
To eliminate the statute of limitations for certain Federal perjury offenses.
Referred to the House Committee on the Judiciary.
H.Res. 1652 · HOUSE3d
Expressing support for the designation of the week beginning on November 9, 2026, as "National School Psychology Week".
Referred to the House Committee on Education and Workforce.
H.Res. 1650 · HOUSE3d
Providing for consideration of the bill (H.R. 1013) to amend the Federal securities laws to enhance 403(b) plans, and for other purposes.
Placed on the House Calendar, Calendar No. 92.
H.R. 10961 · HOUSE3d
To direct the Secretary of Veterans Affairs to report on the Warrior Training Advancement Course of the Veterans Benefits Administration.
Referred to the House Committee on Veterans' Affairs.
H.R. 10968 · HOUSE3d
No Veteran Left Behind: Housing Retention Act of 2026
Referred to the House Committee on Veterans' Affairs.
H.R. 10966 · HOUSE3d
Supporting Veteran Mothers Act of 2026
Referred to the House Committee on Veterans' Affairs.
H.R. 10969 · HOUSE3d
Healthy Meal Time Act of 2026
Referred to the House Committee on Education and Workforce.
H.R. 10970 · HOUSE3d
Cardiovascular Disease Early Detection and Prevention Act of 2026
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently…
H.R. 10962 · HOUSE3d
Justification Oversight and Opportunities for Main Street Act of 2026
Referred to the House Committee on Armed Services.
Showing 15 of 19,857Load 50 more →
119th Congress · H.R. 9418 · Introduced

Access to Innovative Treatments Act of 2026

This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so. Specifically, the CMS must review within 30 days any denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration (FDA). The bill's requirements do not apply if the CMS already conducted such a review within a two-year period. The bill also prohibits the CMS from applying prior coverage determinations that were made for drugs before they were approved by the FDA if such determinations are inconsistent with the drug's approval.

0
Voices Recorded
L3 verified 0
L2 verified 0
Why three axes? · 50-second explainer

1 / 10
Now you know how it works.
Your true verified voice
Your Stance
Should this happen?
0%
0%
0%
Fiscal Judgment
Where do you stand on this government spending?
0%
0%
0%
Authority — Multiple can be selected
Which authority should have control over this? Mark all that apply.
0%
0%
0%
0%

XML scalars

congress
119
type
HR
number
9418
originChamber
House
originChamberCode
H
introducedDate
2026-06-24
updateDate
2026-07-14T20:22:41Z
updateDateIncludingText
2026-07-14T20:22:41Z
title
Access to Innovative Treatments Act of 2026
legislationUrl
https://www.congress.gov/bill/119th-congress/house-bill/9418

Constitutional authority statement (CDATA)

[Congressional Record Volume 172, Number 106 (Wednesday, June 24, 2026)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Ms. BARRAGAN:H.R. 9418.Congress has the power to enact this legislation pursuantto the following:Article 1 Section 8 of the United States Constitution[Page H4246]

Pipeline

Track
federal_presidential
Stage
Introduced
Stage rank
3

Sponsor

  • Rep. Barragán, Nanette Diaz [D-CA-44] · [D-CA-44] · B001300
    Dem-CA-44 current · 5 terms · @RepBarragan · 4 district offices

Sponsor record (congress_legislators)

Bio (legislators)

bioguide
B001300
status
current
official_full
Nanette Diaz Barragán
first
Nanette
middle
Diaz
last
Barragán
suffix
null
nickname
null
birthday
1976-09-15
gender
F

Current term (5 total)

type
rep
state
CA
district
44
class
null
party
Democrat
caucus
null
start
2025-01-03
end
2027-01-03
end_type
null
how
null
url
https://barragan.house.gov
address
2312 Rayburn House Office Building Washington DC 20515-0544
office
2312 Rayburn House Office Building
phone
202-225-8220
fax
null
contact_form
null
rss_url
null

Leadership roles (0)

none

Committee memberships (4)

  • Communications and Technology (house) · house · rank 8
  • Environment (house) · house · rank 5
  • Health (house) · house · rank 5
  • House Committee on Energy and Commerce (house) · house · rank 13 · site

Social media

District offices (4)

  • 701 E. Carson St., Carson City Hall, Carson, CA, 90745 · 310-831-1799 · Wednesday and Thursday, 9:00 a.m. - 5:00 p.m. Please call for an appointment · 33.8322643,-118.2630272
  • 8650 California Ave., South Gate City Hall, South Gate, CA, 90280 · 310-831-1799 · Tuesday and Thursday, 9:00 a.m. - 5:00 p.m. Please call for an appointment · 33.9556898,-118.2051037
  • 638 S. Beacon St, San Pedro, CA, 90731 · 310-831-1799 · 33.7380779,-118.2802296
  • 4201 Long Beach Blvd, Suite 422, Long Beach, CA, 90807 · 310-831-1799 · 33.83467220000001,-118.189654

Other names (0)

none

Sponsor FEC record (fec_live)

Candidate record (candidates) · cycle 2026

candidate_id
H6CA44103
cycle
2026
name
BARRAGAN, NANETTE
party
DEMOCRATIC PARTY
office
House
state
CA
district
44
incumbent_challenge
Incumbent
candidate_status
C
active_through
2026
election_year
null
first_file_date
2015-04-06
last_file_date
2026-01-13
last_f2_date
2026-01-13
address
null

Candidate summary (candidate_summaries) · cycle 2026

cycle
2026
total_receipts
$785,765.20
total_disbursements
$1,178,896.16
cash_on_hand_end_period
$1,088,422.95
debts_owed_by_committee
$0.00
coverage_start_date
2025-01-01
coverage_end_date
2026-06-30

Connected committees (0)

none

Cosponsors (1)

  • Rep. Joyce, John [R-PA-13] · [R-PA-13] · J000302 · Co-sponsored 2026-06-24 · original
    Rep-PA-13 current · 4 terms · @RepJohnJoyce · 6 district offices

Committees (2)

  • Energy and Commerce Committee [House Standing]
    2026-06-24T14:04:10ZReferred To
  • Ways and Means Committee [House Standing]
    2026-06-24T14:04:05ZReferred To

Actions — from XML (4)

  • 2026-06-24IntroReferralH11100via House floor actions
    Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • 2026-06-24IntroReferralH11100via House floor actions
    Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • 2026-06-24IntroReferralIntro-Hvia Library of Congress
    Introduced in House
  • 2026-06-24IntroReferral1000via Library of Congress
    Introduced in House

Actions — from bill_actions table (0)

none

Titles

  • Display Title2026-06-27T12:53:30Z
    Access to Innovative Treatments Act of 2026
  • Short Title(s) as IntroducedIH2026-06-27T12:53:29Z
    Access to Innovative Treatments Act of 2026
  • Official Title as IntroducedIH2026-06-27T12:48:32Z
    To amend title XVIII of the Social Security Act to provide a review process for adverse national coverage determinations with respect to drug coverage under the Medicare program.

Text versions (from XML)

Versions — from bill_versions table (0)

none

Policy area

Health

Summaries

00 · 2026-06-24 · Introduced in House

Access to Innovative Treatments Act of 2026

This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so.

Specifically, the CMS must review within 30 days any denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration (FDA). The bill's requirements do not apply if the CMS already conducted such a review within a two-year period.

The bill also prohibits the CMS from applying prior coverage determinations that were made for drugs before they were approved by the FDA if such determinations are inconsistent with the drug's approval.

Related bills

none

Amendments (0)

none

Laws

none

Committee reports

none

Calendar number

null

CBO cost estimates

none

Latest action

Date
2026-06-24
Text
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Time
null

Dublin Core

format
text/xml
language
EN
rights
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
contributor
Congressional Research Service, Library of Congress
description
This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.

Row fields (debug)

id
17021
congress
119
bill_type
hr
bill_number
9418
bill_slug
hr-9418-119
title
Access to Innovative Treatments Act of 2026
short_title
Access to Innovative Treatments Act of 2026
sponsor_bioguide_id
B001300
sponsor_name
Rep. Barragán, Nanette Diaz [D-CA-44]
sponsor_party
D
sponsor_state
CA
introduced_date
2026-06-24
latest_action_date
2026-06-24
latest_action_text
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
status
Committee
policy_area
Health
subjects_json
[]
govinfo_billstatus_path
BILLSTATUS-119hr9418
raw_billstatus_xml
<?xml version="1.0" encoding="utf-8" standalone="no"?> <billStatus> <version>3.0.0</version> <bill> <number>9418</number> <updateDate>2026-07-14T20:22:41Z</updateDate> <updateDateIncludingText>2026-07-14T20:22:41Z</updateDateIncludingText> <originChamber>House</originChamber> <originChamberCode>H</originChamberCode> <type>HR</type> <introducedDate>2026-06-24</int…
summary_lede
This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so. Specifically, the CMS must review within 30 days any denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration (FDA). The bill's requirements do…
topic_primary
health
topic_secondary_json
[]
action_family
committee_active
response_available
0
response_type
null
response_deadline
null
importance_score
null
consequence_score
null
urgency_score
null
overall_score
null
in_canopy
1
canopy_expires_at
2026-09-22
pipeline_track
federal_presidential
pipeline_stage
introduced
pipeline_stage_rank
3
stable_action_id
hr-9418-119
jurisdiction
federal
lock_status
open
lock_at
null
content_hash
34242cc22bb71ece2897ee9953feb1da3bf90e12af36f1721ff9a39c2860440f
anchored_at
null
anchor_merkle_root
null
source_kind
api_fill
first_seen_at
2026-06-27T11:30:49.408483+00:00
last_seen_at
2026-07-22T11:30:59.053669+00:00
⎔ Anchored0x0000…0000Epoch 2026-Q4